Totally PLC Issues Profit Warning Amid CFO Resignation and Legal Claim Concerns
Totally PLC issues FY25 profit warning after CFO exit and potential £10m+ legal claim; strategic review launched to strengthen balance sheet.
This article covers information on Totally PLC.
LON:TLYA Perfect Storm Hits Totally PLC
When three significant announcements land in a single RNS, you know there’s a story brewing. Totally PLC’s latest update reads like a corporate thriller – profit warnings, abrupt leadership changes, and a lurking legal liability. Let’s unpack this trifecta of turbulence.
Financial Freefall: From Guidance to Gritted Teeth
Six weeks ago, Totally projected £85m revenue and £3.5m EBITDA for FY25. Today? They’re staring down the barrel of £0-£2m EBITDA – a potential 100% wipeout of operating profit. The culprits?
- A sluggish start to a new contract (timing is everything)
- Erosion of high-margin NHS111 work with no redeployment success
- £3.8m exceptional costs from closing that same NHS contract
The real kicker? Management’s now warning of goodwill impairments and has yanked FY26 guidance entirely. That strategic review for fresh funding? Code for “we need cash, pronto.”
The CFO Exit: Reading Between the Resignation Lines
Laurence Goldberg’s immediate departure as CFO raises more eyebrows than a surprise rate cut. No handover period, no successor named – just a vague reference to an “experienced board adviser” stepping in. In regulatory filings, abrupt exits often signal either:
- Disagreements over strategy (that funding review?)
- Concerns about financial reporting (note the impairment warning)
- Or simply someone jumping before being pushed
Until we get clarity, investors should treat this vacuum at the financial helm as a red flag.
The £10 Million Sword of Damocles
Buried in the corporate speak lies a potential bombshell – a 2018 medical negligence claim that could exceed their £10m insurance coverage. Key points:
- New correspondence suggests liability may breach policy limits
- NHS-mandated coverage was only £5m at the time (they carried £10m)
- Medical negligence cases often take years to resolve
This isn’t just about the money – it’s about reputation. Totally’s entire healthcare model relies on NHS trust. Even a whiff of systemic issues could impact future contract bids.
Silver Linings Playbook?
Management isn’t all doom and gloom. They emphasise:
- Ongoing monthly profitability
- Strong customer satisfaction scores
- Pipeline of new contracts
But here’s the rub – “profitable monthly basis” rings hollow when annual guidance collapses. And new contracts take time to boost the bottom line.
Investor Takeaways: What to Watch Next
- Strategic Review Outcome: Equity raise? Asset sales? Debt terms? Each has different dilution risks
- New CFO Appointment: Credibility of successor will be crucial
- Legal Claim Developments: Any reserve provisions in next accounts?
- Contract Wins: Need to see margin details, not just top-line boasts
Totally’s story serves as a reminder that in healthcare services, operational success and financial health can be strange bedfellows. The coming months will test whether this is a temporary stumble or symptom of deeper structural issues. One to watch with both interest and caution.
Related
Keep reading
Investing
Brave Bison Raises System1 Offer to £47.5 Million as Delisting Stakes Grow
Brave Bison's fourth System1 offer values the target at £47.5 million, but the deal remains conditional on securing majority support.
JoshuaSeptember 14, 2026
Investing
Keras Resources pivots to Namibian copper with US phosphate sale and £1.7 million raise
Keras Resources is reshaping itself around Namibian copper, backed by a US phosphate disposal, royalties and a £1.7 million raise.
JoshuaSeptember 14, 2026
Investing
Empyrean Energy adds Austrian gas exposure as equity fundraising looms
Empyrean Energy has agreed an Austrian gas farm-in, but shareholders face exploration risk, a trading halt and likely equity dilution.
JoshuaSeptember 14, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.